Editorial: Central & Peripheral Nervous Systems: Antidepressants: clinical and neuropharmacologic considerations relevant to future drug discovery and development

References

• BENNIE EH, MULLIN JM, MARTINDALE JJ: A double-blind multicenter trial comparing sertraline and fluoxetine In outpatients with major depression. J. din. Psychiatry (1995) 56:229–237.
   Google Scholar
• FISHER F, KENT TA, BRYANT SG: Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J. Clin. Psychiatry (1995) 56:288–296.
   PubMed Web of Science ®Google Scholar
• SHOPSIN B, FRIEDMAN E, GERSHON S: Parachlorophen-ylalanine reversal of tranylcypromine effects in de-pressed patients. Arch. Gen. Psychiatry (1976) 33:811–819.
   PubMed Web of Science ®Google Scholar
• DELGADO PL, CHARNEY DS, PRICE LH, AGHAJANIAN GK, LANDIS H, HENNINGER G: Serotonin function and the mechanism of antidepressant action. Reversal of anti-depressant-induced remission by rapid deletion of plasma tryptophan. Arch. Gen. Psychiatry (1990) 47:411–418.
   Google Scholar
• BLLER P, DE MONTIGNY C: Current advances and trends In the treatment of depression. TiPS (1994) 15:226.
   PubMedGoogle Scholar
• BEL N, ARTIGAS F: Chronic treatment with fluvoxamine Increases extracellular serotonin in frontal cortex, but not in raphé nuclei. Synapse (1993) 15:243–245.
   PubMed Web of Science ®Google Scholar
• DE MONTIGNY C, BLEIR P, CHAPUT Y: Electrophysiologi- cally-identified serotonin receptors in the rat CNS. Effect of antidepressant treatment Neuropharmacology (1984) 23:511–520.
   PubMedGoogle Scholar
• SLIER P, DE MONTIGNY C: Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: single-cell recording studies. J. Clin. Psychopharmacol. (1990) 10:13S–20S.
   Google Scholar
• RICKELS K, AMSTERDAM J, CLARY C, PUZZOLI C, SCHWEIZER E: Buspirone in major depression: a con-trolled study. J. Cfin. Psychiatry (1991) 52:34–38.
   Google Scholar
• WILCOX C, COHN J, FERGUSON J, DALE J, FABRE L: A double-blind, multi center trial of a low dose range and high dose range of gepirone ER compared to placebo In the treatment of depressed outpatients. 35th Annual NCDEU Meeting. Orlando, Florida, May 1995: Abstract #16.
   Google Scholar
• MCGRATH PJ, STEWART JW, QUITKIN FM, WAGER S, JENKINS SW, ARCHIBALD DG, STRINGFELLOW JC, ROBIN-SON DS: Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J. Psychopharm. (1994) 14:347–352.
   Web of Science ®Google Scholar
• BL1ER P, BERGERON R, CHANTAL H: Differential effec- tiveness of pindolol addition in treatment-resistant obsessive compulsive disorder and depression. Annual NCDEU Meeting. Orlando, Florida, May 1995: Abstract #7.
   Google Scholar
• ARTIGAS F, PEREZ V, ALVEREZ E: Pindolol induces a rapid improvement of depressed patients treated with sero-tonin reuptake inhibitors. Arch. Gen. Ps:ychiat. (1994) 51:248–251.
   PubMed Web of Science ®Google Scholar
• YATES M. LEAKE A, CANDY JM, FA1RBAIRN IG, FERRIER IN: 5-HT2 receptor changes in major depression. Biol. Psychiatry (1990) 27:19–32.
   Google Scholar
• MANN J, MCBRIDE PA, MCERWIN BS: Increased serotonin and adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiat. (1986) 43:954–959.
   PubMed Web of Science ®Google Scholar
• ANDRADE R, ARANEDA R: 5-Hydroxytryptamine 2 and 5-hydroxytrypta.mine lA receptors mediate opposingresponses on membrane excitability in rat association cortex. Neuroscience (1991) 40:399–412.
   Google Scholar
• EISON AS, YOCCA FD, GIANUTSOS G: Effect of chronic administration of antidepressant drugs on 5-HT2-medi-ated behavior in the rat following noradrenergic or serotonergic deactivation. J. Neural Trans. (1991) 84:19–32.
   Web of Science ®Google Scholar
• OGREN SO, FUXE K, AGNATI LF, GUSTAFSSON JA, JANSSEN G, HOLM AC: Re-evaluation of the indolamine hypothesis of depression: evidence for a reduction of functional activity of central 5-LIT systems by antide-pressant drugs. J. Neural Trans. (1979) 40:85–103.
   Google Scholar
• EISON AS, EISON MS, TORRENTE JR, WRIGHT BS, YOCCA FD: Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharm. Bull. (1990) 26:311–315.
   PubMed Web of Science ®Google Scholar
• FONTAINE R, ONTIVEROS A, ELLIE R, KENSLER Tr, ROBERTS DL, KAPLITA S, ECKER J, FALUDI G: A double-blind comparison of nefazodone, imipramine, and pla-cebo in major depression. J. Clin. Psychiatry (1994) 55:234–241.
   PubMed Web of Science ®Google Scholar
• RICKELS K, SCHWEIZER E, CLARY C, FOX I, WEISE C: Nefazodone and imipramine in major depression: a placebo-controlled triaL Brit. j Psychiat (1994) 164:802–805.
   Google Scholar
• SHARPLEY AL, WALSH AE, COWEN PJ: Nefazodone - a novel antidepressant - may increase REM sleep. Biol. Psychiatry (1992) 31:1070–1073.
   PubMed Web of Science ®Google Scholar
• MARTINELLI MJ, BLOOMQUIST W, PETERSON BC, COHNML: Arnesergide and structurally-related nor-D-ergoli-nes: 5-HT receptor interactions in the rat. J. Med. Chem. (1993) 36:2671–2675.
   PubMed Web of Science ®Google Scholar
• YOCCA FD, EISON AS, GYLYS J, SMITH D, REUDIGER E, VANDERMAELEN C, TEMPLE DL: BMS 181101: a novel serotonergic antidepressant 31st Annual ACNP Meeting. Jan Juan, Puerto Rico, December 1992: Abstract P15.
   Google Scholar
• FEIGHNER PJ: The role of venlafaxine in rational anti-depressant therapy. J. Clin. Psychiat. (1994) 55:62–70.
   PubMed Web of Science ®Google Scholar
• TOLEFSON GD, THOMPSON RG, HEILLIGENSTEIN SJ, WONG D, FARIES DE, HYSLOP DL: Is the potent, dual uptake inhibition of norepinephrine and serotonin by LY248686 (duloxetine) associated with a more rapid antidepressant response? 32nd Annual ACM' Meeting. Honolulu, Hawaii, December 1993: Abstract P23.
   Google Scholar
• PICH ME, LORANG M, YAGENEH M, DE FONSECA FR, RABER J, KOOB GF, WEISS F: Increase of extracellular corticotropin-releasing factor-like itrununoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by mi-crodialysis. J. Neuroscience (1995) 15:5439–5447.
   PubMed Web of Science ®Google Scholar
• DE SOUZA EB: Role of cortieotropin-releasing factor in neuropsychiatric disorders and neurodegenerative dis-eases. Annual Reports in Med. Chem. (1990) 25:215–224.
   Web of Science ®Google Scholar
• GRIGORIADIS DE, PEARSALL D, DE SOUZA EB: Effects of chronic antidepressant and benzodlazepine treatment on corticotropin-releasing factor receptors in rat brain and pituitary. Neuropsychopharm. (1989) 2:53–60.
   PubMed Web of Science ®Google Scholar